Continuous Chromatography Patents: Who Leads, Where the Gaps Are 2026
- 86.3% of all 95 records sit with just five assignees, and 96.8% with ten — this is a field held by a narrow group, not a broad crowd.
- Filings peaked in 2017 at 41 and have declined since, with the 2022 midpoint at only 6 — momentum looks flat to falling even before the recent-year publication lag is accounted for.
- C07K peptide/protein claims cover 65.3% of records while separation-process claims under B01D sit at just 25.3%, pointing to where the engineering-side claim space is thinner.
What the patent record shows about continuous chromatography
Continuous chromatography — periodic counter-current and multi-column continuous capture in particular — has moved from a resin-utilization efficiency play into a control-systems and validation problem. The 95 records in scope here span 2015 through the 2026 cut-off, and the claim language clusters tightly around column-switching control, buffer consumption and validation rather than novel resin chemistry itself. That skew toward process control over materials is visible directly in the IPC composition: peptide and protein claims (C07K) dominate at 65.3% of records, while material-analysis claims (G01N) and separation-process claims (B01D) trail well behind.
Filing activity peaked in 2017 and has trended down since, with the 2022 midpoint sitting at only 6 records — a pattern consistent with an early wave of foundational control-system patents followed by a quieter period of incremental filing. Because publication typically lags filing by around 18 months, the most recent years understate true activity, but the shape of the decline from the 2017 peak predates that lag and is unlikely to be fully explained by it.
Filing trend and technology composition
Two views of the same 95-record dataset: how filing activity has moved year over year, and how those filings distribute across IPC subclasses.
Filing trend, 2015–2026
Filings rose to a peak of 41 in 2017, then fell through the 2022 midpoint of 6 and have stayed low since. Recent years are understated by the typical 18-month publication lag, but the overall trajectory has been declining rather than accelerating.
Technology composition by IPC subclass
C07K (peptides and proteins) covers 65.3% of the 95 records, ahead of G01N (material analysis and testing) at 29.5% and B01D (separation processes) at 25.3%. Smaller subclasses — C12Q, A01H, A23L, B01J and C07H — each sit at 2.1% or below, marking the thinnest-claimed corners of the field. Records can carry more than one class, so these shares add to more than 100%.
Shares are the percentage of the 95 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Continuous Chromatography for Downstream Processing with Eureka
This page is one run against one query. Ask Eureka your own question about continuous chromatography for downstream processing and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
Control and optimization of continuous chromatography process (US20240295533A1)
Filed by Tata Consultancy Services, this application targets control of charge-variant composition during continuous chromatography using a distributed control system, programmable logic controllers, a LAN setup and a Python-based operator interface — an explicit move from mechanical column-switching logic toward a software-defined control layer.Abstract condensed from the original filing.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20180339244A1 | Method for controlling continuous chromatography and multi-column chromatography arrangement | 21 |
| 2 | WO2017140881A1 | Protein purification | 20 |
| 3 | EP3173782A1 | Method for controlling continuous chromatography and multi-column chromatography assembly | 16 |
| 4 | WO2019016154A1 | chromatography | 13 |
| 5 | WO2018122191A1 | Monitoring performance in continuous chromatography | 10 |
| 6 | US20190346412A1 | Monitoring Performance in Continuous Chromatography | 7 |
| 7 | US20200331960A1 | chromatography | 6 |
| 8 | US20220146416A1 | An NIR based real-time control of loading in protein a chromatography | 3 |
| 9 | US20240295533A1 | Control and optimization of continuous chromatography process | 2 |
| 10 | US11958881B2 | Optimization method for capturing proteins by multi-column continuous chromatography (MCC) | 2 |
Citation counts favour older filings simply because they have had more time to be cited; read them as a signal of influence within this corpus, not as a ranking of current importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for strategy
Three signals worth acting on: where the claim density sits, how the field's momentum has moved, and where the filing footprint by geography actually falls.
A narrow group holds the core claim space
With the leader alone accounting for 59 of 95 records and the top five holding 86.3% of all records in scope, this is not a fragmented field. A new entrant filing broad control-system claims is likely to run into prior art from a small number of established holders rather than a diffuse crowd.
Filing activity has cooled since its 2017 peak
The field's busiest year on record was 2017 at 41 filings; by the 2022 midpoint, activity had fallen to 6. Recent years will read low in part because of the roughly 18-month publication lag, but the multi-year decline before that lag kicks in suggests genuine cooling rather than a reporting artifact.
Filing footprint centres on Europe and the US, with a real Asia-Pacific and PCT tail
Europe (EPO) and the United States lead as receiving offices, but Israel, India, WIPO/PCT and Singapore each carry a meaningful share of filings — a sign that protection strategies for this technology are already multi-jurisdictional rather than concentrated in one home market.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous chromatography for downstream processing, with the prior art for and against each one.
Who is filing, and what is still open
The ranked assignee list is short — 13 companies — and heavily front-loaded, which leaves specific technical corners with little or no claim coverage.
One assignee dominates the filing record
The top-ranked assignee alone accounts for 59 of the 95 records in this dataset, a scale no other holder in the ranking approaches. Anyone assessing freedom to operate in column-switching control or continuous-capture validation should treat this holder's portfolio as the first prior-art check.
A mid-tier cluster sits well below the leader
Fifth place in the ranking holds 5 records — a steep drop from the leader's 59. This gap suggests the mid-tier holders are filing around specific applications or geographies rather than building broad platform coverage.
A long tail of single- or near-single-filers
Tenth place in the ranking holds just 1 record, and the ranking closes out at 96.8% of all records for the top ten. Entrants further down the list are typically defending a single application or academic filing rather than a commercial platform.
| Assignee | Recent year | YoY |
|---|---|---|
| UCB Biopharma SPRL | 0 | — |
| Merck Patent GmbH | 0 | — |
| Tata Consultancy Services Limited | 0 | — |
| Indian Institute of Technology | 0 | — |
| Karlsruhe Institute of Technology | 0 | — |
| GE Healthcare Bio-Sciences AB (Sweden) | 0 | — |
| Zhejiang University | 0 | — |
| ANTON MICHEL | 0 | — |
Where to take this analysis
The dataset points to a concentrated, cooling field with specific gaps in the claim map. The next step is turning that into a filing or freedom-to-operate decision.
Map freedom to operate against the leader's portfolio
With one assignee holding 59 of 95 records, any new filing in column-switching control or continuous-capture validation should start with a claim chart against that portfolio specifically, not a generic prior-art sweep.
Explore assignee portfolios in EurekaTest the under-claimed branches before drafting
The chips above — enzyme/DNA-linked capture, plant feedstocks, food-grade separation, catalytic resin cycles and nucleic-acid co-purification — each carry only one or two records industry-wide. Confirm they are genuinely open, not just under-searched.
Run a white-space search in EurekaRe-check momentum once recent years settle
Because publication lags filing by about 18 months, 2025 and 2026 figures will rise as more records post. Revisit the trend in six to twelve months before concluding the decline from the 2017 peak has bottomed out.
Track filing trends in EurekaCommon questions about continuous chromatography patents
One assignee leads clearly, holding 59 of the 95 records in this dataset — far ahead of any other holder in the 13-company ranked list. The top five assignees combined hold 86.3% of all records, and the top ten hold 96.8%, so the field is concentrated rather than fragmented. A freedom-to-operate review in this space should prioritise the leading holder's portfolio before looking at the long tail of single-filing entrants.
Filing activity peaked in 2017 at 41 records and has since declined, with the 2022 midpoint sitting at just 6 records. Recent years will look artificially low because publication typically lags filing by around 18 months, so 2025 and 2026 figures are not final. Even accounting for that lag, the multi-year decline from the 2017 peak suggests the field has cooled from its earlier filing intensity rather than simply having unpublished recent activity.
Peptide and protein-related claims under IPC class C07K dominate, covering 65.3% of the 95 records in scope. Material-analysis and testing claims (G01N) follow at 29.5%, and separation-process claims (B01D) at 25.3%. Because a single record can carry multiple IPC classes, these figures add to more than 100%, but the ranking itself is informative: control and analytical claims currently outweigh pure separation-hardware claims.
The thinnest-claimed IPC subclasses in this dataset are C12Q (enzyme/DNA-related measuring), A01H (plant breeding), A23L (food and beverage applications), B01J (catalytic processes) and C07H (sugars and nucleic acids), each at 2.1% of records or below. These are not necessarily unimportant applications — they may simply be under-explored from a claims perspective, which makes them worth a dedicated novelty search before drafting new applications in adjacent process-control or validation claims.
US20240295533A1, filed by Tata Consultancy Services, covers control and optimization of a continuous chromatography process specifically aimed at managing charge-variant composition in biotherapeutic products. Its distinguishing feature is the control architecture: a distributed control system paired with programmable logic controllers, a LAN setup and a Python-based operator interface, rather than a novel resin or column design. For engineers building software-defined control layers around continuous capture, this filing is a relevant reference point on how far process-control claims already extend in this space.
Research Continuous Chromatography for Downstream Processing in depth with Eureka
Go past this page: query the whole continuous chromatography for downstream processing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.